EVIDENCE USA SPEAKERS

Rafael Alfonso, Director, Analytics and Innovation, Value Evidence and Outcomes, G.S.K.

Abhik Bhattacharya, Senior Director of R.W.I. and Global Analytics, Astellas Pharma U.S.

Sue Caleo-Naeyaert, Senior Director, Biosimilars Policy North America, EMD Serono

Efrem Castillo, MD, Chief Medical Officer, UnitedHealthcare Medicare & Retirement, UnitedHealth Group

Efrem Castillo at Market Access US 2016

Ms Lovena Chaput, Executive Director, Commercial Operations, Americas & Asia Pacific, Raptor Pharmaceuticals

Ms Lovena Chaput at Market Access US 2016

Steve Clark, Vice President of Business Development and Consulting, Optum

Dr Omar Dabbous, Head of Quantitative Science Payer Evidence Group, Halozyme

Dr Omar Dabbous at Market Access US 2016

Diane DiGangi Trench, Vice President Managed Markets, Takeda

Diane DiGangi Trench at Market Access US 2016

Jon Easter, Director, Center for Medication Optimization through Practice and Policy (CMOPP), U.N.C. Eshelman School of Pharmacy

Anna Forsythe, Managing Partner, Purple Squirrel Economics

Anna Forsythe at Market Access US 2016

Elangovan Gajraj, Senior Technical Adviser, National Institute for Health and Care Excellence

Mr Matthew Gordon, Senior Director, Observational Research, PAREXEL

Lorna Graham BSc MSc, Associate Director Project Management, Worldwide Clinical Trials

Lorna Graham BSc MSc at Market Access US 2016

Liz Helms, President and CEO, California Chronic Care Coalition

Dorothy Hoffman, Head US Health Policy, Eli Lilly and Co

Ms Linda House, President, Cancer Support Community

Ms Linda House at Market Access US 2016

Laura Housman, MPH, MBA, Founder, Access Solutions Consulting

Tom Hubbard, Vice President of Policy Research, The Network for Excellence in Health Innovation

Usman Iqbal, Senior Medical Affairs Leader-Neuroscience Global Med Affairs, AstraZeneca

Ira Klein, Senior Director, Health Care Quality Strategy, Strategic Customer Group, Janssen

Linda Lander, Director, Market Access, Sun Pharmaceuticals Ltd

Susanne Laningham, Executive Director, Global Value, Access & Policy, Amgen

Gil L'Italien, Executive Director, Global Health Economics and Outcomes Research, Alexion

Ms Julie Locklear, Vice President and Head of Health Economics and Outcomes Research, E.M.D. Serono Inc

Morgan Molloy, Head of US Commercial, Spark Therapeutics

Matthew Monberg, Director and Value Evidence Lead, Merck and Company

Stephen Murby, Spokesperson on Biosimilars, International Alliance of Patients' Organizations

Jeff Myers, CEO, Medicaid Health Plans of America

Dr David Nash, MD MBA, Dean, Jefferson College of Population Health

Dr David Nash, MD MBA at Market Access US 2016

Mary Kay Owens, Executive Director, Institute for Healthcare Innovation Strategies

Ed Pezalla, Vice President, National Medical Director for Pharmaceutical Policy and Strategy, Aetna

James Prodafikas, Director, Global Market Access – Acute Care/Hospital, Merck and Co Inc

James Prodafikas at Market Access US 2016

Dominic Robinson, Global Market Access Specialty Franchise Partner, GSK

Dr Tehseen Salimi, VP, Health Economics and Outcomes Research, US Medical and Scientific Affairs, Takeda

Michael Sanky, Vice President, Data & Advanced Analytic Tools Consulting, Optum Life Sciences

Thom Schoenwaelder, Vice President PAREXEL Access, PAREXEL International

Mr Vanja Sikirica, Senior Director of Value Evidence and Outcomes, GlaxoSmithKline

Brian Solow, Chief Medical Officer, Optum Life Sciences

Dr Boxiong Tang, Senior Director, Teva Pharmaceuticals United State of America

Dr Jeff Trotter, President, Continuum Clinical

Mr Frank Wiegand, Vice President Global Medical Affairs & Market Access, Neurosciences, Janssen

Dr James Wu, Director, Outcomes Research, Amgen

Dr James Wu at Market Access US 2016